CRMD analyst estimates
CorMedix (CRMD) analyst ratings, the average price target and its range, and every firm's latest call.
CRMD analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Sep 23, 2026 | Oppenheimer | CorMedix initiated with an Outperform at Oppenheimer | $15.00 |
| Apr 28, 2026 | RBC Capital | CorMedix price target raised to $14 from $13 at RBC Capital | $14.00 |
| Mar 6, 2026 | Leerink Partners | CorMedix (CRMD) PT Lowered to $13 at Leerink Partners | $13.00 |
| Jan 23, 2026 | H.C. Wainwright | CorMedix price target lowered to $13 from $18 at H.C. Wainwright | $13.00 |
| Jan 21, 2026 | RBC Capital | CorMedix price target lowered to $13 from $22 at RBC Capital | $13.00 |
| Jan 8, 2026 | Truist Financial | CorMedix price target lowered to $16 from $20 at Truist | $16.00 |
| Oct 21, 2025 | RBC Capital | CorMedix price target raised to $22 from $21 at RBC Capital | $22.00 |
| Aug 8, 2025 | H.C. Wainwright | CorMedix price target lowered to $17 from $20 at H.C. Wainwright | $17.00 |
| Mar 13, 2024 | RBC Capital | CorMedix (CRMD) PT Lowered to $9 at RBC Capital | $9.00 |
- 7 firms rate CRMD: 7 buy, 0 hold, 0 sell.
- The average price target is $15.00 from 1 analysts, from $15.00 to $15.00.
Updated 2026-11-02 17:14 UTC